The trademark application REZYMNAV was filed by Johnson & Johnson, a U.S. corporation (the "Applicant"). The application was published for oppositions on October 18, 2020, and it was registered by office on January 25, 2021 without any oppositions.
The application was filed in Dutch (English was selected as the second language).